<DOC>
	<DOCNO>NCT00003908</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness docetaxel plus carboplatin treating patient metastatic recurrent head neck cancer .</brief_summary>
	<brief_title>S9902 Docetaxel Plus Carboplatin Treating Patients With Metastatic Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess survival patient metastatic recurrent squamous cell carcinoma head neck receive docetaxel carboplatin . II . Assess time treatment failure response rate ( unconfirmed confirm complete partial response ) patient population . III . Evaluate toxicity regimen patient population . OUTLINE : Patients receive docetaxel IV 1 hour immediately follow carboplatin IV 30 minute day 1 . Courses repeat every 3 week absence unacceptable toxicity disease progression . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter death . PROJECTED ACCRUAL : A total 62 patient accrue study 18 month .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma head neck Metastatic disease diagnosis OR Persistent , metastatic recurrent disease follow surgery and/or radiotherapy No newly diagnose nonmetastatic disease Bidimensionally measurable disease Demonstrated progressive disease measurable site within previous radiotherapy port PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 OR Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Calcium great upper limit normal ( ULN ) Creatinine great 1.5 time ULN OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within past 5 year except adequately treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission No neuropathy sensory great grade 1 No history hypersensitivity reaction Polysorbate 80 PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior carboplatin cisplatin No prior chemotherapy recurrent disease No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy ( except oral contraceptive treatment osteoporosis ) Radiotherapy : See Disease Characteristics At least 28 day since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics At least 28 day since prior surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>